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Abstract: A number of biomarkers are used clinically and many protein-based assay methods are available. Improvements 
in the method to utilize speciﬁ  c antibodies have led to remarkable progress in clinical diagnosis using biomarkers. Proteomics 
studies to identify better biomarkers have been performed worldwide by using a protein-based comprehensive method. The 
detection rate of conventional biomarkers can not improve further. Now is a time that a breakthrough is needed. We previously 
proposed mRNA, which is circulating in the body, as a novel material for biomarkers. mRNA is an unexpectedly useful 
molecule, not only because it can detect genes with a low expression level in protein, but also because it can detect the 
expression from non-coding RNA precursor genes or gene products with limited secretion from the cells. Circulating mRNA 
has been thought to be unstable in blood containing RNase. We conﬁ  rm that mRNA remains at the same level for 24 hours 
after blood sampling. Unlike DNA, the RNA molecule can reﬂ  ect events in the human body which occurred within a day, 
resulting in an early diagnosis of diseases. We report the possibility to detect and quantify cancer-derived mRNAs circulat-
ing in human vessels. We introduce the detection of serum mRNA as a useful biomarker of human malignancies.
Abbreviations: hTERT: human telomerase reverse transcriptase protein; HCC: hepatocellular carcinoma; hTR: human 
telomerase RNA template; HCV: hepatitis C virus; HBV: hepatitis B virus; AH: adenomatous hyperplasia; AAH: atypi-
cal adenomatous hyperplasia; LC: liver cirrhosis; CH: chronic hepatitis; AFP: α-fetoprotein; DCP; des-γ-carboxy pro-
thrombin; ALT: alanine aminotransferase; Alb: albumin; EGFR: Epidermal growth factor receptor; non-small cell lung 
cancer; NSCLC: non-small cell lung cancer; small cell lung cancer; SCLC; ADC: adenocarcinoma; SCC: squamous cell 
carcinoma antigen; SqCC: squamous cell carcinoma; CEA: carcinoembryonic antigen; CYFRA (21–1): cytokeratin 19 
fragment; CNA: circulating nucleic acids.
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Background of Circulating Nucleic Acids
Since the discovery of circulating nucleic acids in plasma in 1948, many diagnostic applications have 
emerged. Small amounts of circulating nucleic acids (CNA) are present in the plasma of healthy indi-
viduals. Increased levels of plasma CNA have been reported in a number of clinical disorders such as 
cancer, stroke, trauma, myocardial infarction, autoimmune disorders and pregnancy-associated com-
plications. CNA has received special attention because of its potential application as a non-invasive, 
rapid and sensitive tool for molecular diagnosis and monitoring of the diseases, and the prenatal diag-
nosis of fetal genetic diseases. A simple blood test for cancer detection has been the quest of many 
researchers in particular. Recently, CNA instead of a protein has been used in practical diagnosis. 
Cell-free circulating nucleic acids in plasma/serum derived from tumor tissues, have received much 
interest. Although it is well known that higher concentrations of DNA (deoxyribonucleic acid) are pres-
ent in the plasma of cancer patients sharing some characteristics with DNA of tumor cells (1, 2, 3, 4), 
it has been reported that mRNAs detected in blood reﬂ  ects the early event in a clinical condition (5). 
Since RNA (ribonucleic acid) in plasma/serum may be a suitable source for the development of non-
invasive diagnostic, prognostic and follow-up tests for cancer, this discovery has provided us with very 
promising assays useful for early detection of malignancies.512
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Circulating RNA as Diagnostic 
Source
A recent development in this new ﬁ  eld is the 
identification of tumor-related RNA in the 
plasma/serum of cancer patients (6). These 
include tyrosine kinase mRNA (7), telomerase 
components (8, 9), the mRNAs that are encoded 
by different tumor-related genes (10, 11, 12, 13, 
14), and viral mRNA (14). As more RNA than 
DNA markers can be detected in the circulation 
of cancer patients, an assay using RNA markers 
produced higher sensitivity than other conven-
tional assays. In one study, two telomerase mark-
ers of breast cancer yielded 44% positive rates 
(8). However, telomerase RNA seems to be a 
promising marker as it can be detected even in 
the serum of patients with small, undifferentiated 
breast cancers without any metastatic lesions. 
Dasi et al. showed that circulating telomerase 
RNA is a sensitive marker, using real-time 
reverse transcription-polymerase chain reaction 
(real time RT-PCR) (9). In their study, 8 of 9 
plasma samples from colorectal cancer patients 
and 9 of 9 plasma samples from patients with 
lymphoma tested positive for human telomerase 
reverse transcriptase. The plasma samples of all 
10 healthy individuals were negative.
Methods
To detect a transcript of interest in cell-free 
serum, quantitative real-time RT-PCR was per-
formed by using 1 µl of RNA extract and 2 µl of 
SYBR Green I (Roche, Basel, Switzerland) in a 
One Step RT-PCR kit (Qiagen, Tokyo, Japan) 
using LightCycler with reproducibility. After 
blood sampling, RNA was extracted with DNase 
treatment after three steps of centrifugation of 
serum as previously reported with a few modiﬁ  -
cations mainly including a precise gravity control 
of centrifugation to obtain cell-free serum and 
mRNA quantiﬁ  cation using optimized primer set 
(INTEC Web and Genome Bioinformatics, 
Tokyo, Japan) (8, 16). Other minor modiﬁ  cations 
are as follows. RNA from 200 µl of serum was 
dissolved in 200 µl of water. Quantitative RT-PCR 
was performed by using 1 µl of RNA extract and 
2 µl of SYBR Green I (Roche, Basel, Switzerland) 
in a One Step RT-PCR kit (Qiagen, Tokyo, Japan). 
RNA in serum was extracted by using the same 
volume of serum and dried up to 20-fold concen-
tration. RNAs from tissues were extracted using 
TRIzol Reagent according to manufacture’s 
instructions (Invitrogen Corp., Carlsbad, CA, 
U.S.A.). RT-PCR consisted of an initial incuba-
tion at 50 °C for 30 min followed by a 12-min 
incubation at 95 °C, then 50 cycles at 95 °C 
(0 s), 55 °C (10 s), and 72 °C (15 s), and a 20 
second melting at 40 °C. The dynamic ranges of 
real-time PCR analysis for mRNA of interest were 
more than approximately 5 to 10 copies in this 
assay. We could therefore exclude the possibility 
of false negative results in serum samples from 
patients and controls. To examine signiﬁ  cant 
clinicopathological ﬁ  ndings affecting mRNA and 
other markers, the difference among diseases and 
stratiﬁ  ed categories in each clinical parameter 
was statistically evaluated. Tumors, tumor size, 
number of tumors, histological ﬁ  ndings including 
differentiation degree of tumors, clinical staging, 
and the presence of metastasis were analyzed. 
Correlations among biomarkers were calculated 
using Pearson’s relative test. To assess the accu-
racy of diagnostic tests, the matched data sets 
(patients with reference diseases or healthy indi-
viduals and those with malignancies) for bio-
markers were analyzed using receiver operator 
characteristic (ROC) curve analysis. This assay 
demonstrated a strong linear relation between 
copy number and PCR cycles using RNA controls 
(r
2   0.99) (Fig. 1A). A correlation of mRNA 
between malignant tissue and serum was analyzed 
to examine whether serum mRNA is derived from 
the original tissues by both paired t test and 
Spearman’s test. Optimal predictive cut-off val-
ues and the sensitivity/speciﬁ  city for mRNA 
expressions, and positive predictive value (PPV)/
negative predictive value (NPV) during carcino-
genesis were calculated. All the primers were 
optimally designed (INTEC Web and Genome 
Informatics corp., Tokyo, Japan).
Biomarkers in Hepatocellular 
Carcinoma
Introduction
HCC is a highly fatal cancer that affects approx-
imately half a million people worldwide (17, 18). 
The incidence of HCC has been rising rapidly and 
this increase has generated concern among clini-
cians, researchers and policy makers. Major risk 
factors of HCC include hepatitis C virus (HCV), 
hepatitis B virus (HBV), nonalcoholic 513
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steatohepatitis (NASH) and heavy alcohol 
consumption. Development of HCC is generally 
thought to depend on the rapid and long-term 
repeated cell turnovers. This indicates that HCC 
expands clonally from the hepatocytes which have 
been suffering intense inﬂ  ammation for a long 
duration, causing senescence. It would be advan-
tageous to detect the evidence of clonal occur-
rence of HCC at an early stage using a newly 
developed modality.
Tumor markers for HCC
AFP has been used as a serum marker for HCC in 
humans for many years and has a sensitivity of 
39%–65% and speciﬁ  city of 76%–94% (19). How-
ever, the detection rate can be improved using 
ultrasonography (US) (20). Several biomarkers such 
as DCP, AFP-L3 (21), human hepatocyte growth 
factor (HGF), and insulin-like growth factor-1(IGF-1) 
are promising, but none of these markers have been 
validated for clinical use compared to AFP. There 
is an urgent need for novel biomarkers for the detec-
tion of early-stage HCC (22). The marker should be 
speciﬁ  c for HCC, enabling the detection of HCC at 
an early stage, easily measured and the test should 
be reproducible, minimally invasive and acceptable 
to patients and physicians (23). Among biomarkers 
identiﬁ  ed at this stage, DCP and AFP-L3 have been 
most extensively studied and seem to be promising. 
DCP has a sensitivity of 28% to 89% and speciﬁ  city 
of 87% to 96%. AFP-L3 has a sensitivity of 36% to 
96% and speciﬁ  city of 89% to 94%. Most of these 
markers are measured by enzyme immunoassay 
(EIA) to detect proteins due to the advantage of its 
stability.
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Figure. 1 (A) In each quantitative assay, a strong linear relation was demonstrated between copy number and PCR cycles using RNA 
controls for concentration (r = 0.99 for hTERT mRNA: left; r = 1.0 for EGFR mRNA: right). The dynamic ranges of real-time PCR analysis 
for hTERT mRNA and EGFR mRNA were more than approximately 5~10 copies in this assay and we were able to exclude the possibility of 
false negativity in serum samples from patients and controls. Control hTERT mRNA for standardization was generated using T7 RNA poly-
merase in pLIXN-hTERT cDNA kindly provided from Dr. H. Tahara (Hiroshima University, Japan) and another control EGFR mRNA was 
similarly generated using pCRII-TOPO-EGFR (Invitrogen Japan K.K, Tokyo, Japan) retroﬁ  tted from pME18SFL3-EGFR purchased as FLJ 
cDNA clone commercially (TOYOBO, Tokyo, Japan). (B) A dot plot represents the signiﬁ  cant correlation of (left) hTERT mRNA level in serum 
in lung cancer tissues in 23 patients and of (right) EGFR mRNA level in serum in lung cancer tissues in 9 patients. Only a minority of the 
cases that were positive for mRNA in the tissue specimens (n = 23 for hTERT, n = 9 for EGFR) is included in this analysis. Positive is deﬁ  ned 
as “above the predictive cut-off values for both mRNAs obtained from this study in 112 lung tumors and 80 healthy individuals”. These data 
were analyzed by the paired t test (p   0.01 for both) and non-parametric Spearman’s test (p = 0.021 for hTERT mRNA, p = 0.002 for EGFR 
mRNA, respectively). The data were evaluated by logarithm of quantiﬁ  cation.514
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Application of the hTERT mRNAs in 
blood for diagnosis
The telomerase enzyme complex has two major 
subunits and its expression is mainly regulated by 
a catalytic subunit (human telomerase reverse 
transcriptase, hTERT) (2). Since many kinds of 
mRNAs could be found in the plasma and serum 
of healthy individuals and cancer patients (3), it 
has been suggested that the detection of cancer-
related gene expression in the serum is very useful 
for the diagnosis and follow-up of patients. The 
hTERT mRNA or endogenous RNA component 
derived from cancer cells did not seem to be 
detectable in serum due to its instability by RNase 
(ribonuclease) in serum. However, since RNAs in 
serum are stable at most for 24 hour after drawing 
blood (24, 25), it has been suggested that they can 
even be detected in blood by a narrow margin 
(7, 26). hTERT mRNA can be detected in serum 
from breast cancer patients and its maximum 
sensitivity and speciﬁ  city were at most 40% and 
100% respectively (8). We previously reported that 
approximately 88% was qualitatively positive for 
the detection of HCC-derived RNA in serum (16), 
indicating that serum RNA can be applied for the 
diagnosis of other cancers as well as HCC. We 
singled out hTERT mRNA as the most appropriate 
molecule for cancer diagnosis. In this context, we 
focused on HCC, since hTERT mRNA is gradually 
increased during the multi-step process of 
hepatocarcinogenesis (27).
Materials, methods, and results of 
hTERT mRNA in HCC
This study enrolled 104 consecutive patients [64 
patients with HCC, 20 with liver cirrhosis (LC), 
and 20 with chronic hepatitis (CH)]. All the HCC 
patients had LC as the underlying liver disease. 
The mean ages of patients with HCC, LC and CH 
were 66, 64 and 55 years respectively. Sixty-six 
patients were infected with HCV, 30 with HBV, 
3 with both viruses and 5 with no viral markers. 
Patient gender, age, etiology, Pugh score, Child 
classiﬁ  cation, underlying liver disease, total bili-
rubin (TB), albumin (Alb), alanine aminotrans-
ferase (ALT), AFP, AFP-L3, DCP, HCV titer, 
HCV subtype, tumor number, tumor size, differ-
entiation degree of tumor, and presence of metas-
tasis were evaluated. Fifty healthy individuals 
including 12 females (range 22–83 years old: 
mean age 58 years) served as controls. To study 
whether hTERT mRNA in serum is produced and 
released from HCC in the liver, we harvested the 
surgically resected HCC tissues and sera in 
another 10 HCC patients. Both hTERT mRNA 
and AFP mRNA expressions showed stepwise 
up-regulation with disease progression and the 
quantiﬁ  cation was signiﬁ  cantly higher in HCC 
than in LC, CH, and healthy individuals 
(p   0.0001, p   0.0001 and p   0.0001 in 
hTERT; p = 0.011, p = 0.044 and p   0.0001 in 
AFP, Fig. 2). Alb, tumor size, number of tumors, 
degree of differentiation of tumors and the pres-
ence of metastasis were signiﬁ  cantly associated 
with hTERT mRNA expression (p   0.05, 
p   0.01, p   0.0001, p   0.0001 and p   0.05, 
respectively, Table 1). To examine correlations 
among biomarkers, we calculated Pearson’s rela-
tive test and found that hTERT mRNA level was 
signiﬁ  cantly correlated with AFP mRNA level (P 
  0.05). Signiﬁ  cant correlation of hTERT mRNA 
in HCC tissues with that in serum was also 
observed (p   0.01, Fig. 1B). DCP (p   0.05), 
AFP level (p   0.05) and AFP-L3 (p   0.05) 
showed a signiﬁ  cant correlation with tumor size 
when it was stratiﬁ  ed as  20 mm, 20–30 mm and 
 30 mm in diameter. Furthermore, hTERT 
mRNA expression was closely associated with 
well- and moderate-degree of differentiation of 
HCC (p   0.05). hTERT mRNA were superior to 
other tumor markers in differentiating HCC from 
chronic liver disease by Friedman’s test (p   0.01). 
ROC curve analyses showed that the sensitiv-
ity/speciﬁ  city of hTERT mRNA for HCC were 
88.2%/68.7% (Fig. 3A). At that time, optimal 
predictive cut-off values for both mRNA expres-
sions were 12 500 copies/0.2 ml and 3000 
copies/0.2 ml, respectively. In the assay, the sen-
sitivity/speciﬁ  city in each tumor marker during 
hepatocarcinogenesis is shown in Table 2B. 
Positive predictive value (PPV)/negative predic-
tive value (NPV) during hepatocarcinogenesis 
was 0.862/0.870 in hTERT mRNA. PPV/NPV in 
AFP mRNA, AFP level, AFP-L3 and DCP is 
0.695/0.741, 0.812/0.389, 0.778/0.277 and 
0.852/0.405 respectively. Control hTERT mRNA 
for standardization was generated using T7 RNA 
polymerase in pLIXN-hTERT cDNA.
Summary
Currently available tumor markers for hepatocel-
lular carcinoma (HCC) are α-fetoprotein (AFP), 
lens culinaris agglutinin-reactive AFP (AFP-L3), 515
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Dot plot showing the quantification of hTERT mRNA and AFP  mRNA
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Figure 2. (left) hTERT mRNA levels and (right) AFP mRNA level (on logarithmic scales) in serum from patients with HCC, LC, CH, and 
healthy individuals by real-time RT-PCR. The 95% conﬁ  dence interval in each group is shown beside the dots. Signiﬁ  cant differences between 
4 groups are shown in the upper part of the ﬁ  gure. NL, individual with normal liver: OL, other liver diseases: CH, chronic hepatitis: LC, liver 
cirrhosis: HCC, hepatocellular carcinoma.
and des-γ-carboxy prothrombin (DCP). However, 
the diagnostic potential of these markers cannot 
surpass abdominal ultrasonography (US) as 
modalities to detect small HCC in the early stage. 
There is a need to develop additional sensitive 
markers to improve the early detection of HCC. 
We introduce a newly developed quantitative 
method for detecting serum hTERT mRNA, 
which has a clinical significance in HCC 
diagnosis.
In 154 subjects, including 64 with HCC, 20 
with liver cirrhosis, 20 with chronic hepatitis, 
and 50 healthy individuals, we measured serum 
hTERT mRNA using the newly developed real-
time quantitative RT-PCR with SYBR Green I. 
Briefly, we examined its sensitivity and speci-
ficity in HCC diagnosis, clinical significance in 
comparison with other conventional tumor 
markers than mRNAs, and its correlations with 
the clinical parameters by using multivariate 
analyses and Friedman’s test.
Serum hTERT mRNA showed higher values in 
patients with HCC than in those with chronic liver 
diseases. hTERT mRNA expression was demon-
strated to be independently correlated with clinical 
parameters such as tumor size (p   0.001), number 
(p   0.001) and differentiation degree (p   0.001). 
The sensitivity and speciﬁ  city of hTERT mRNA 
in HCC detection were 88.2% and 70.0% respec-
tively. hTERT mRNA proved to be superior to AFP 
mRNA (71.6 and 67.5), AFP (69.3 and 60.0) and 
DCP (81.5 and 63.5), respectively (Table 2-A). 
Importantly, hTERT mRNA in serum was corre-
lated with that in HCC tissue.
Serum hTERT mRNA is a novel and available 
marker for HCC detection. We are conducting a 
large-scale study with approximately 500 patients 
on the feasibility of HCC diagnosis. This method 
will be suitable for a number of hTERT-positive 
malignancies, and for the quantiﬁ  cation of the 
expression of genes of which protein products are 
weakly expressed.516
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ROC curve analysis of hTERT mRNA for the respective malignancies
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Figure 3. Receiver operator characteristic (ROC) curve analysis of the hTERT mRNA and/or EGFR mRNA expressions in comparison with 
conventional tumor markers. The curves shown were obtained by processing quantiﬁ  ed raw data by SPSS II software and the sensitivity/
specificity values were predicted from the area under the curves and the calculated data. (A) For hepatocellular carcinoma, 
(B) for lung cancer (NSCLC), (C) for ovarian malignancies, and (D) for uterine malignancies.
Biomarkers in lung cancer (non 
small cell lung cancer: NSCLC)
Introduction
Lung cancer is the leading cause of malignancy-
related mortalities (28) with little change in the 
survival rates over the past two decades (29). Non-
small cell lung cancer (NSCLC) now accounts for 
about three-quarters of all cases of lung cancer (30). 
Most patients die of progressive metastatic disease 
despite the development of new therapeutic strate-
gies and advances in surgical treatment. Serum 
tumor markers are non-invasive diagnostic tools 
for malignant tumors and they are commonly used 
for the screening of cancer and as an indicator of 
the treatment-effect. In small cell lung cancer 
(SCLC), neuron-speciﬁ  c enolase (NSE), and pro-
gastrin-releasing peptide (proGRP) are effective 
markers. In NSCLC, carcinoembryonic antigen 
(CEA), squamous cell carcinoma related antigen 
(SCC) and cytokeratin 19 fragment (CYFRA 21-1) 
are commonly used for screening. At least one 
marker among CEA, SCC and CYFRA is positive 
in approximately 70% of patients with NSCLC 
(30). According to the histological category, the 
positive rates of CEA and CYFRA are high in 
adenocarcinoma (ADC) patients, and the positive 
rates of CYFRA and SCC are high in squamous 
cell carcinoma patients. Although the standard 
diagnostic procedures such as X-ray examinations, 
conventional tumor markers and bronchial lavage 
(BL) are important for the detection of lung cancer, 
they are still not sensitive enough to detect lung 
cancer at an early clinical stage.
Tyrosine kinase activity of epidermal growth 
factor (EGFR) promotes tumor cell proliferation, 
cell survival, angiogenesis, invasion, and metasta-
sis, and its speciﬁ  c inhibition by geﬁ  tinib, a syn-
thetic anilinoquinazoline, has been demonstrated 518
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(32). EGFR is expressed in 20% to 80% of tissue 
specimens of NSCLC (33), but its expression has 
been observed in progressive type of SCLC (34). 
EGFR may therefore be a potential molecule for 
diagnosis or a good target that determines respon-
siveness to EGFR-targeted therapies (35). Some 
groups have reported that cell-free circulating 
hTERT mRNA in plasma can be detected in 12% 
of patients with lung cancer (NSCLC) (5), suggest-
ing that hTERT mRNA detected in blood may be 
applicable for lung cancer as a diagnostic vehicle.
This study on pulmonary malignancy also dem-
onstrates the clinical usefulness of hTERT mRNA, 
especially when combined with EGFR mRNA as 
a novel tumor marker in primary lung cancer for 
early detection and diagnosis. This method would 
be useful for patients or ethnic groups in which 
drugs targeting EGFR in lung cancer are thought 
to be effective.
Patients and sample collection
This study enrolled 89 consecutive patients with 
lung tumor (75/89 with NSCLC, 6/89 with SCLC 
and LCLC, and 8 with benign tumor) who were 
admitted to the National Hospital Organization 
Yonago Medical Center between July 2003 and 
December 2004 (Table 3). The mean age of the 
patients was 63 years (range 22 to 90 years). The 
patients were diagnosed based on serological 
examinations, chest X-rays, (helical) computed 
tomography (CT), chest and brain magnetic reso-
nance imaging (MRI), cytological examinations, 
and transbronchial, percutaneous, and thoraco-
scopic lung biopsies. The ﬁ  nal diagnosis was made 
using surgically resected specimens for pathology. 
Patient demographics, diagnostic tumor size, num-
ber of tumors, tumor markers including CEA, SCC, 
CYFRA, proGRP, NSE, TPA, SLX, history of 
smoking (estimated by Pack-Year index), the pres-
ence of metastasis or recurrence, and clinical stage 
(IA~IV) were evaluated. Twenty-seven healthy 
individuals including 12 females (range 22 to 
90 years old: mean age 58 years) served as controls. 
To examine any change in gene expression in 
serum before and one month after surgical treat-
ment in the same patients and to examine their 
significance as tumor markers, we quantified 
hTERT mRNA and EGFR mRNA expression in 9 
patients with lung cancer. Control EGFR mRNA 
was generated using pCRII-TOPO-EGFR (Invit-
rogen Japan K.K, Tokyo, Japan) retroﬁ  tted from 
pME18SFL3-EGFR and purchased as a FLJ cDNA 
clone (TOYOBO, Tokyo, Japan).
mRNA quantiﬁ  cation and clinical 
parameters
In each quantitative assay, a strong linear relation 
was demonstrated between copy number and PCR 
cycles using RNA controls for concentration 
(r
2   0.99 for hTERT mRNA and EGFR mRNA; 
Fig. 1A). The copy numbers of hTERT mRNA 
(p   0.01) and EGFR mRNA (p   0.01) were 
signiﬁ  cantly higher in the lung cancer patients 
than in the healthy individuals. Pearson’s relative 
Table 2. The sensitivity/speciﬁ  city and PPV/NPV of each tumor marker for hepatocellular carcinoma are shown. 
PPV: positive predictive value, NPV: negative predictive value (A). Statistical signiﬁ  cance in each tumor marker 
during hepatocarcinogenesis is shown (B).
 Sensitivity  Speciﬁ  city  p value  PPV/NPV
AFP 0.693  0.600  0.002  0.812/0.389 
AFP-L3 0.563  0.925  0.304  0.778/0.277
DCP 0.815  0.635   0.001 0.852/0.405
AFP mRNA  0.716  0.675   0.001 0.695/0.741
hTERT mRNA  0.882  0.700   0.001 0.862/0.870
  Tumor marker  CH/LC  →  HCC   LC    →    HCC
   (n  = 40)  (n = 64)     ( n   = 20)          (n = 64)
 AFP  level    0.376  0.532
 AFP-L3    0.144  0.228
 DCP    0.317  0.479
 AFP  mRNA    0.001  0.001
 hTERT  mRNA     0.001   0.001
A.
B.519
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test to clinical parameters denoted that the hTERT 
mRNA level was signiﬁ  cantly associated with the 
presence of active liver disease, TPA, SCC and 
number of tumors (p   0.05, p   0.05, p   0.001, 
and p   0.05, respectively). EGFR mRNA was 
signiﬁ  cantly correlated with the number of occu-
pied lobular segment, metastasis, recurrence, and 
clinical staging (p   0.05, p   0.05, p   0.01, 
and p   0.01, respectively). A comparison of 
hTERT-negative (less than the predictive cut-off 
value) patients with hTERT-positive (more than 
the predictive cut-off value) patients, hTERT-
negative patients were signiﬁ  cantly correlated 
only with a pathological diagnosis (ADC) in the 
other clinical factors by Kruskal-Wallis test 
(p = 0.02, respectively).
Statistical analysis and ROC curve 
analysis
Clinicopathological ﬁ  ndings that were analyzed 
by one-way ANOVA showed signiﬁ  cant relations 
to hTERT and EGFR expression in the serum 
(Table 3). Smoking, tumor size, number of tumors 
and the presence or absence of metastasis or recur-
rence, was signiﬁ  cantly associated with hTERT 
mRNA expression (p   0.05, p   0.01, p   0.01, 
p   0.01 and P   0.05, respectively). The number 
of tumors (p   0.05), tumor size (p   0.05), recur-
rence (p   0.05) and clinical staging (p   0.05) 
were signiﬁ  cantly correlated with EGFR mRNA 
expression. In lung cancer, all tumor markers 
showed no signiﬁ  cant relations with pathological 
diagnosis. CEA level showed a signiﬁ  cant correla-
tion with smoking (p   0.05) (36). SCC level was 
correlated with the number of tumors (p   0.05), 
tumor size (p   0.05) and metastasis (p   0.05). 
CYFRA level was correlated with the number of 
tumors (p   0.05), tumor size (p   0.05), metas-
tasis (p   0.05) and recurrence (p   0.05). To 
examine the sensitivity and speciﬁ  city of tumor 
markers for diagnosis of lung cancer, an ROC curve 
analysis was performed (Fig. 3B). The sensitivity 
of CEA, SCC, CYFRA, EGFR mRNA and hTERT 
mRNA for lung cancer was 40.1%, 58.9%, 48.8%, 
60.8% and 71.8%, respectively (Table 4). On the 
other hand, the speciﬁ  city of CEA, SCC, CYFRA, 
EGFR mRNA and hTERT mRNA was 74.4%, 
58.3%, 74.2%, 62.5% and 72.5%, respectively. 
The positive predictive value (PPV) and negative 
predictive value (NPV) of hTERT mRNA were the 
highest of the tumor markers examined. 
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Furthermore, the combination of hTERT mRNA 
and EGFR mRNA improved the sensitivity and 
specificity (PPV and NPV) to 82.8%, 77.7%, 
89.8%, and 73.7%, respectively. The optimal cut-
off values for hTERT mRNA and EGFR mRNA 
were calculated as 10
3.76 copies/0.2 ml and 10
2.81 
copies/0.2 ml, respectively. The cut–off values of 
hTERT mRNA combined with EGFR mRNA, 
which did not signiﬁ  cantly correlate with each 
other, were calculated as the summation of both 
measurements prior to the logarithm of quantiﬁ  ca-
tion, and showed no relative signiﬁ  cance to each 
other. The combination of hTERT and EGFR 
mRNA was superior to any of the other tested 
serum markers used for isolation.
Correlation of hTERT mRNA and 
EGFR mRNA detection in paired 
serum and tumor tissue samples
The copy number of hTERT mRNA in serum was 
signiﬁ  cantly correlated with that in cancer tissue 
(p   0.05). The copy number of EGFR mRNA in 
the serum was signiﬁ  cantly related to that in the 
cancer tissue specimens (p   0.01), Fig. 1B). The 
data suggest that both RNAs in the serum are 
derived from lung cancer tissue specimens.
Evaluation of serum hTERT 
quantiﬁ  cation as a tumor biomarker
The quantitative decrease in hTERT mRNA one 
month after surgical treatment, compared with that 
before the treatment shown in Fig. 4A, suggests 
that hTERT mRNA is a useful biomarker which 
can be applied to cancer patients. Although EGFR 
mRNA tended to decrease after the treatment, this 
decrease was not statistically signiﬁ  cant.
Summary
We attempted to clarify its clinical signiﬁ  cance 
as a biomarker for lung cancer. In 89 patients with 
lung cancer and 27 individuals without, we mea-
sured serum hTERT mRNA and epidermal growth 
factor receptor (EGFR) mRNA levels, using a 
quantitative one-step real-time RT-PCR assay. We 
examined its sensitivity and speciﬁ  city in lung 
cancer diagnosis, its clinical signiﬁ  cance in com-
parison with other tumor markers, and its correla-
tion with the clinical parameters using 
multivariate analyses and the correlation relative 
test. The copy number of serum hTERT mRNA 
was independently correlated with tumor size 
(p   0.05), tumor number (p   0.05), the pres-
ence of metastasis and recurrence (p   0.05) and 
smoking (p   0.05). EGFR mRNA correlated 
with tumor size (p   0.05), tumor number 
(p   0.05), recurrence (p   0.05) and clinical 
stage (p 0.05). The sensitivity/speciﬁ  city in lung 
cancer diagnosis was 71.8%/72.5% for hTERT 
mRNA and 60.8%/62.5% for EGFR mRNA 
respectively. hTERT mRNA was superior to other 
tumor markers in lung cancer diagnosis. Both 
mRNAs in serum were signiﬁ  cantly correlated 
with those in lung cancer tissues (p   0.05 for 
hTERT; p   0.05 for EGFR). The copy number 
of hTERT mRNA signiﬁ  cantly decreased after 
the surgical treatment. The combination of both 
mRNAs improved the sensitivity/speciﬁ  city to 
82.8%/77.7%, suggesting that hTERT mRNA, 
especially when combined with EGFR mRNA, is 
a novel and excellent biomarker for pulmonary 
Table 4. Sensitivity/speciﬁ  city of each tumor marker for lung cancer.
 Sensitivity  Speciﬁ  city  p value  PPV/NPV  Cut-off point
hTERT mRNA  71.8  72.5  0.006  77.5/66.7  3.76(10
x copy)
EGFR mRNA  60.8  62.5  0.023  66.7/40.7  2.81(10
x copy)
CYFRA 48.8  74.2  0.016  65.0/50.0  1.3(ng/ml)
SCC 58.9  58.3  0.032  20.7/87.5  1.5(ng/ml)
CEA 40.1  74.4  0.376  65.0/39.1  2.8(ng/ml)
hTERT + EGFR  82.8  77.7  0.001  89.8/73.7  5.38(10
x copy)
mRNA
The sensitivity/speciﬁ  city values are 71.8%/72.5% for hTERT mRNA, 60.8%/62.5% for EGFR mRNA, 48.8%/74.2% for CYFRA, 58.9%/58.3% 
for SCC, and 40.1%/74.4% for CEA. In the diagnostic assessment of sensitivity and speciﬁ  city, hTERT mRNA (0.718/0.725) was identiﬁ  ed 
as the most excellent tumor marker.PPV: positive predictive value, NPV: negative predictive value. Sensitivity, speciﬁ  city,p value, and PPV/
NPV of hTERT + EGFR mRNA were calculated, based on the summation of each logarithmic cut-off values.522
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malignancies to diagnose and assess the clinical 
stage and effects of treatments.
Biomarkers in Gynecologic 
Malignancies
Introduction
Ovarian cancer is the ﬁ  fth most common cancer in 
women. Despite the fact that it is highly curable if 
diagnosed early, ovarian cancer kills more women 
each year than all other gynecologic malignancies 
(37). There are no proven methods of prevention, 
and it is often a rapidly progressive and fatal dis-
ease. The only validated marker for ovarian cancer 
is CA125, which is detectable in the serum of more 
than 80% of women with ovarian cancer. In con-
trast, cervical cancer is the third leading cause of 
cancer death in women. Over half a million new 
cases are diagnosed every year worldwide. The 
most common histological type of cervical cancer 
is squamous cell carcinoma which accounts for 
more than 80% of all cervical cancers. An increas-
ing number of reports indicate that other factors 
are involved along with human papilloma virus 
(HPV) to induce cervical carcinogenesis. A rou-
tinely used biomarker for advanced cervical cancer 
is SCC, which is detectable in the serum of less 
than 50% of women with cervical cancer. CA125 
and SCC are reliable only in monitoring the 
response to treatment or recurrence, but not as a 
diagnostic or prognostic marker (38). Thus, there 
is considerable interest in identifying molecular 
diagnostic and prognostic indicators to guide treat-
ment decisions.
It is well known that one of the carcinogenic 
biomarkers, human telomerase reverse transcrip-
tase (hTERT) (39,    40), is not only expressed in 
mild dysplastic lesions in cervices (41), but is also 
often expressed in gynecological malignancies.
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Figure 4. (A) A dot plot representing the signiﬁ  cant correlation between hTERT mRNA level in serum and that in gynecologic cancer tissues 
in 9 patients. Only a minority of the cases that were positive for mRNA in the tissue specimens (n = 8 for hTERT) is included in this analysis. 
Positive is deﬁ  ned as “being above the predictive cut-off values for both mRNAs obtained from this study in 89 lung tumors and 27 healthy 
individuals”. These data for hTERT mRNA were analyzed by Wilcoxon’s test and the paired t test (p < 0.028 and p = 0.035, respectively). 
The data are evaluated by a logarithm of quantiﬁ  cation. (B) The quantiﬁ  cation of both mRNAs in the serum before, during, and 7 days after 
any treatment including chemotherapy or surgical treatment is stratiﬁ  ed into three groups. The data are evaluated by a logarithm of quanti-
ﬁ  cation. hTERT mRNA expression among the three groups was evaluated by the paired t test (*p < 0.05). N.S. means not signiﬁ  cant.523
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Patients and sample collection
A total of 176 consecutive patients (47 patients 
with ovarian cancer, 63 with uterine cancer, 2 with 
other gynecologic cancer, 2 with border lesions, 
and 62 with benign diseases) that were admitted 
to Tottori University Hospital between December 
2003 and January 2005, were enrolled in this study. 
Of the patients with benign disease, 41 had benign 
ovarian diseases including 11 with an ovarian 
dermoid cyst, 4 had endometriosis in the ovary, 13 
had an ovarian cyst and 21 had benign uterine 
diseases including 1 patient with invasive hyda-
tidiform mole, 4 with adenomyosis of the uterus, 
14 with uterine myoma and 2 with uterine prolapse. 
Twenty healthy patients served as controls. The 
mean age of the patients was 55 years (range 18 to 
85 years). CA125 (ChemilumiACS-CA125II, 
Bayer Japan, Tokyo) and SCC (SCC RIAbeads, 
SRL, Tokyo, Japan) in the serum were measured 
in routine laboratory tests. Human papilloma virus 
(HPV) was not examined for uterine lesions. The 
patients were diagnosed by chief complaints, ultra-
sonography, computed tomography (CT), CA125 
or SCC, cytology or biopsy under internal exami-
nation, histological examination after laparoscopy 
or surgical therapy. The clinicopathological ﬁ  nd-
ings, gender, age, etiology, histological ﬁ  ndings, 
CA125 for ovarian disease, SCC for uterine dis-
ease, tumor size, clinical staging, and presence of 
recurrence were evaluated.
mRNA quantiﬁ  cation and clinical 
parameters
According to this quantitative assay, the copy 
numbers of hTERT mRNA were signiﬁ  cantly 
higher in the gynecologic cancer patients than in 
the healthy individuals (p   0.01, each). Clini-
copathological ﬁ  ndings showed signiﬁ  cant rela-
tions to hTERT mRNA in the serum (Table 5). 
By multivariate analysis, the hTERT mRNA level 
was signiﬁ  cantly correlated with age, the pres-
ence of cancer, ovarian disease in organs, ovarian 
malignancies, tumor size, and CA125 (p   0.001, 
p = 0.004, p = 0.045, p = 0.004, p = 0.044, 
p = 0.035 and p   0.001, respectively). On the 
other hand, EGFR mRNA did not show any 
signiﬁ  cant correlation with any parameters or 
with other markers. SCC was significantly 
associated with uterine malignancies (p = 0.021). 
With the Friedrich test, hTERT mRNA, SCC, and 
CA125 were signiﬁ  cantly correlated with the 
clinical stage (p   0.001, p = 0.033, and 
p = 0.028, respectively). Pearson’s relative test 
between clinical parameters revealed that the 
hTERT mRNA level was signiﬁ  cantly associated 
with the presence of cancer (p = 0.009) and, in 
the ovary, with CA125 and age (p = 0.049 and 
p = 0.045, respectively).
To examine the sensitivity and speciﬁ  city of 
tumor markers for diagnosis of gynecologic malig-
nancies, ROC curve analysis showed the sensitiv-
ity/speciﬁ  city of hTERT mRNA for gynecologic 
malignancies to be 74.4%/74.1% (data not shown). 
For ovarian malignancies, area under the curve 
(AUC) of hTERT mRNA and CA125 were 90.9% 
and 83.3%, respectively, and the sensitivity/speci-
ficity of hTERT mRNA in ovarian cancer is 
95.0%/90.0% (Fig. 3C). The sensitivity/speciﬁ  city 
of hTERT mRNA and SCC in uterine cancer is 
70.1%/81.5% and 50.0%/67.5% respectively. On 
the other hand, the sensitivity/speciﬁ  city of hTERT 
mRNA and CA125 in ovarian cancer is 100%/76.5% 
and 100%/75.5% respectively. For uterine malig-
nancies, AUC of hTERT mRNA and SCC were 
72.2% and 30.6% (Fig. 3D), respectively. The 
optimal cut-off values for hTERT mRNA and 
EGFR mRNA were calculated as 10
4.1 copies/0.2ml 
and 10
2.99 copies/0.2 ml, respectively.
Evaluation of serum hTERT quantiﬁ  -
cation as a tumor biomarker
All patients were stratiﬁ  ed into three categories 
based on the timing of blood sampling (before, 
during, and after therapy) and the therapeutic 
effect such as anti-tumor agents or surgical treat-
ment was estimated by a t test. Although there was 
no correlation between before and during blood 
sampling, hTERT mRNA signiﬁ  cantly decreased 
after therapy, compared with before and during 
the therapy (p   0.05, each) (Fig. 4B). This sug-
gests that the measurement of hTERT may be 
useful for the evaluation of a therapeutic effect. 
In uterine malignancies, hTERT mRNA and SCC 
were signiﬁ  cantly useful biomarkers to evaluate 
therapeutic effect (p = 0.001 and p = 0.026, respec-
tively). In ovarian malignancies, hTERT mRNA 
and CA125 were signiﬁ  cantly useful for the diag-
nosis of cancer (p = 0.001 and p = 0.043, 
respectively). The copy number of hTERT mRNA 
in serum was signiﬁ  cantly correlated with that in 
cancer tissue (p = 0.028 in Wilcoxon’s test, 
p = 0.035 in the paired t test).524
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Summary
We attempted to elucidate the diagnostic evaluation 
of serum hTERT mRNA for gynecologic malignan-
cies with our method. In 174 female patients with 
gynecological lesions (47 with ovarian lesions, 63 
with uterine lesions, 2 with malignancies in other 
gynecological lesions, and 62 benign lesions) and 
20 healthy individuals, we measured serum hTERT 
mRNA and EGFR mRNA by our real-time 
quantitative RT-PCR in the same way as lung can-
cer. We examined their sensitivity and speciﬁ  city 
in cancer diagnosis, clinical signiﬁ  cance in com-
parison with conventional tumor markers, and their 
correlations with the clinical parameters by using 
multivariate analyses. Serum hTERT mRNA 
showed higher values in patients with gynecologic 
cancers than in those with benign diseases and 
healthy individuals. The hTERT mRNA level 
independently correlated with the presence of 
cancers (p = 0.004 for both ovarian and uterine 
cancer) and clinical stage (p   0.001). The sensi-
tivity and speciﬁ  city of hTERT mRNA in cancer 
diagnosis was 74.4% and 74.1%, respectively. 
The hTERT mRNA level showed a signiﬁ  cant cor-
relation with CA125 by Pearson’s relative test 
(p = 0.035) and with histological ﬁ  ndings in ovar-
ian cancer by the Friedrich test (p   0.004). EGFR 
mRNA never displayed any differences between 
Table 5. Statistical analysis of the comparison between gynecologic tumor markers and clinical parameters.
Clinical parameters  # of patients  Multivariate analysis
          hTERT  mRNA  SCC  CA125
          p  p  p
Age mean: 55 years old    <0.001  N.S  0.028
(range 18 to 85 )     
Etiology 
 malignant        89  0.004
 border        3 
 benign         20
Organ 
 Uterus        52  N.S   
 cervical       37
 body        5  0.045  N.S  N.S
 Ovary        39     
 Others        1     
Histological ﬁ  ndings     
 Uterus          N.S  0.021  N.S
  Squamous cell carcinoma  29     
 Endometrioid    15
 Others        22
Ovary         0.004  N.S  <0.001
 Serous        24
 Mucinous      9
 Others        22 
Tumor size         0.044  N.S  N.S
Tumor marker     
 SCC(ng/ml)        N.S    N.S.
 CA  125(mAU/ml)       0.035  N.S. 
Staging 
 1        29    <0.001  0.033  0.028
 2        8
 3        12     
 4 
Before theraphy     60  N.S  N.S  0.043
During       6
After       26
Recurrence 
 yes        33  N.S  N.S  N.S
 no        59525
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the diseases. hTERT mRNA is useful for diagnos-
ing gynecologic cancer and is superior to conven-
tional tumor markers. Therefore, serum hTERT 
mRNA is a novel and available biomarker for 
gynecologic malignancies.
Discussion
In a subsequent quantitative study, we have 
improved the sensitivity to detect the instable 
nucleotides in blood by removing cellular proteins 
and minimizing the contamination of cellular 
nucleic acids in serum and a primer set which can 
amplify hTERT mRNA efﬁ  ciently (35). Further-
more, the correlation between tumor tissue and 
serum in terms of hTERT mRNA was demonstrated 
in Figure 1B, suggesting that hTERT mRNA 
detected in serum is derived from tumor cells. AFP 
is widely used as a reliable marker of HCC, not in 
earlier stage but in advanced stage (42). Since HCC 
recurs repeatedly and polyclonally due to biologi-
cal characteristics even after any treatments, the 
monitoring of serum hTERT mRNA might make 
it possible to diagnose the recurrence earlier. In 
this respect, we prospectively have to conduct a 
follow-up study after the treatment of HCC (man-
uscript in preparation). hTERT mRNA expression 
was found to be closely associated with a well to 
moderate degree of differentiation of HCC. 
Nakashio et al. previously reported a signiﬁ  cant 
correlation between HCC differentiation and 
telomerase expression (43). The results in the pres-
ent study conﬁ  rmed their ﬁ  ndings. hTERT mRNA 
showed more sensitivity and speciﬁ  city compared 
with AFP mRNA in HCC diagnosis. AFP mRNA 
did more sensitivity and speciﬁ  city compared with 
AFP level (5). The higher speciﬁ  city of hTERT 
mRNA may be related to the fact that AFP mRNA 
is produced in HCC cells and injured hepatocytes. 
However, hTERT is produced mainly in HCC cells. 
Waguri et al proved that hTERT mRNA in circulat-
ing cancer cells, derived from HCC tissues, can be 
detectable by using a cell-sorting system that they 
developed. The authors indicated that HCC cells 
released from the original HCC were within 10 
mm in size (44) and suggested that the value is 
consistent with the result of the mRNA detection 
method. Our studies suggest that quantiﬁ  cation of 
hTERT mRNAs in serum has diagnostic implica-
tions for NSCLC and ovarian cancer as well as 
HCC. We will evaluate the correlation between 
prognosis and hTERT mRNA (45), and assess the 
availability of hTERT mRNA in other hypervas-
cular cancers by comparing hTERT mRNA with 
other tumor markers. We are performing a large-
scale study with more than 500 patients to conﬁ  rm 
our results for the monitoring and detection of 
HCC. Since our assay is difficult to perform 
manually, we are developing an automatic, concise 
and rapid diagnostic apparatus with a reagents kit 
to be introduced into clinics, even at the primary 
care level. In the diagnostic ﬁ  eld of medicine, cur-
rent patent laws involved in intellectual property 
rights are limiting diagnostic progression. This 
method will be suitable for the diagnosis of a num-
ber of hTERT-positive malignancies and for can-
cer-speciﬁ  c RNA genes or other genes showing 
weak protein levels. The systemic introduction of 
this assay into the primary care level can be 
expected in the near future.
In pulmonary and gynecological malignancies, 
we suggest that the correlation with response/sur-
vival may be more evident if this more sensitive 
mRNA-based detection assay is used. The induc-
tion of a combination of hTERT mRNA and EGFR 
mRNA into the early diagnosis of lung cancer may 
improve the follow-up of patients. Since the data 
shows that hTERT and EGFR mRNA levels are 
associated with previously detected lung cancers, 
it does not demonstrate whether the method is suf-
ﬁ  ciently robust for early detection. However, the 
evaluation of hTERT mRNA combined with EGFR 
mRNA may be a useful biomarker to diagnose and 
assess the clinical stage and effect of treatments in 
patients with lung cancer. Further case-control 
studies should be planned to evaluate both long-
term and former smokers who do not have lung 
cancer. hTERT mRNA is useful in the diagnosis 
of gynecologic cancers as well and is superior to 
conventional tumor markers. Therefore, serum 
hTERT mRNA is a novel and available biomarker 
for gynecologic malignancies.
Investigations into other disease-
speciﬁ  c mRNAs and the clinical 
signiﬁ  cance
In other malignancies such as thyroid cancer and 
pancreatic cancer (in preparation), this assay has 
been applied (manuscript under preparation for 
publication). We are investigating other disease-
speciﬁ  c mRNAs as biomarkers to be applied in 
the clinic or in primary care. The ﬁ  eld of medical 
care we are engaged in is the diagnosis of 526
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intractable disease (Table 6). It is necessary to ﬁ  nd 
improved mRNA such as hTERT, compared to 
Positron Emission Tomography (PET), as a diag-
nostic vehicle. We are studying inﬂ  ammatory 
diseases such as fulminant hepatitis (46) or acute 
respiratory distress syndrome (in preparation), and 
lifestyle-related diseases, autoimmune diseases, 
and disease from gene dysfunction which are dif-
ficult to diagnose or estimate the clinical 
condition.
Conclusion
Additional diagnostic methods (e.g. imaging), or 
combination of other biomarkers would be still 
needed to determine the type and location of the 
tumor. In our investigations, circulating mRNA is 
a very sensitive molecule to detect diseases in 
organs with rich blood ﬂ  ow or systemic inﬂ  am-
matory disease. The presence of acute phase dis-
eases, including cancer progression, could be 
detected if mRNA is tested for within one day of 
blood sampling. However, this assay has a limita-
tion. It can be inﬂ  uenced by organs with rich blood 
ﬂ  ow such as the liver. The disease of interest may 
be masked, for example in patients suffering from 
progressive liver disease. Based on these actual 
circumstances, it is likely that further develop-
ments over the next few years in the ﬁ  eld of cir-
culating RNA will provide us with new diagnostic 
and monitoring possibilities.
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